NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Xenetic Biosciences, Inc. XBIO
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.0M
▲ 19.0% vs FY2024
EPS · FY25
$-1.58
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-40.0%
Net margin · FY25
-90.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.0M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 90 cents on every revenue dollar this year.
Per share
USD -1.58
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-40.0%
Return on equity, FY2025
ROE
Operating margin-95.2%
Net margin-90.1%
Return on assets-35.1%
Each USD of equity lost 40 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+46.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+20.4%
+46.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.4M
total assets, end of FY2025
Total assetsUSD 8.4M
EquityUSD 7.4M
CashUSD 7.9M
Current ratio8.32×
Equity funds 88% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.58
−2.57
−2.71
−4.61
−0.55
−1.70
−6.33
−9.66
−0.41
−7.84
−2.96
−0.11
−0.07
−0.05
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−40.0
−50.1
−35.3
−40.9
−36.9
−74.0
−94.2
−60.3
−23.6
−475.9
−146.4
−123.9
−51.4
−30.5
Shares out B
0.00
0.00
0.00
0.00
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.14
0.12
0.12
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
45 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed